被点评研究:Castañeda-González JP, Chaves JJ, Parra-Medina R. Multiple mutations in the EGFR gene in lung cancer: a systematic review. Transl Lung Cancer Res 2022;11:2148-63. 多重突变的EGFR基因在肺癌患者中少见但不...
参考文献 [1] Gu Hangye, Lü Qing, Chen Yong. Research Progress of Gefitinib in the Treatment of Non-Small Cell Lung Cancer with EGFR Gene Mutation[J]. Chinese Pharmacy, 2023, 34(14): 1788-1792. 编辑:Potato
参考文献: Hyun Chang,et al.,Epidermal Growth Factor Receptor Gene Amplification Predicts Worse Outcome in Patients with Surgically Resected Non-Adenocarcinoma Lung Cancer,Clinical Lung Cancer (2018), doi: 10.1016/j.cllc.2018.06.003. 癌度为患者提供了参加临床试验的渠道,免费试用PD-1等靶向药物。想要入...
参考文献: Hirsch FR,et al.,Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in NonCSmall-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy,J Clin Oncol. 2008 Jul 10;26(20):3351-7. Douillard JY,et al., Relationship Between EGFR Exp...
EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. J Thorac Oncol 2011; 6:947-950.Helland A, Skaug HM, Kleinberg L, Iversen ML, Rud AK, Fleischer T, Sagerup C, Solberg S, Jorgensen L, Ariansen S, Brustugun OT (2011) EGFR gene alterations in a...
NSCLC is often associated with epidermal growth factor receptor(EGFR)gene mutations. Currently,epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)are the preferred first-line treatment option for EGFR-mutated NSCLC. Furmonertinib is the second third-generation EGFR-TKI marketed in ...
[3] XIA C,ZENG F,ZHANG Y. EGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patientoriginally driver gene-negative[J]. Thorac Cancer,2019,10(5):1256 - 1259. [4] GELATTI A C Z,DRILON A,SANTINI F C. Optimizing the sequencing of tyrosine kinase inhi...
▶基因融合（gene fusion）是指由于某种机制（如基因组变异）使得两个不同基因的部分序列或全部序列融合到一起，形成了一个新的基因。目前，已经有部分临床前研究发现奥希替尼联合吉非替尼阻止了获得性二线EGFR耐药基因的形成。此外，在2020年ASCO（美国临床肿瘤学会）年会上，一项美国学者进行的I/II期临床研究（NCT...
Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene. First-line therapy for these patients is often osimertinib, a third-generation EGFR TKI. Erlotinib, gefitinib...
In lung adenocarcinoma, oncogenic EGFR mutations co-occur with many tumor suppressor gene alterations; however, the extent to which these contribute to tumor growth and response to therapy in vivo remains largely unknown. By quantifying the effects of inactivating 10 putative tumor suppressor genes in...